A universal material transfer agreement with a thirty-day default
Getting a cell line, mouse model or antibody from another lab can take six months of paperwork. Funders would require a standard agreement that goes through automatically unless someone objects within thirty days.
Funders and journals require that materials generated with their support are shared under the Uniform Biological Material Transfer Agreement or an equivalent open template (for example the OpenMTA for tool reagents), with institutions committing to a thirty-day default-approve process for non-commercial requests and to deposit widely used reagents in repositories (Addgene, ATCC, JAX, EurOPDX). Material access delays are a documented cause of failed replications and slow translation; the fix is procedural, not scientific, and costs almost nothing.
- Secrecy and intellectual property block collaboration · Companies with complementary drugs rarely test them together, and data that could answer questions stays locked up.
- Preclinical results do not reproduce · Fewer than half of landmark cancer biology findings reproduce when someone else tries.
Pages like this
not linked directly; found by shared links- IdeaShared reference organoid and PDX panels that every lab can test against
Shares Cancer Models (PDCM Finder) & HCMI, Patient-derived xenografts, Patient-derived organoids, Preclinical results do not reproduce.
- IdeaScoop protection and co-publication norms to reduce academic secrecy
Shares Promote academics for trials completed, data shared and findings replicated, Secrecy and intellectual property block collaboration, Preclinical results do not reproduce.
- IdeaAn independent replication institute that re-tests key preclinical cancer findings before trials
Shares Patient-derived xenografts, Patient-derived organoids, Preclinical results do not reproduce.
- IdeaMake in vivo metastasis screens a required step in drug discovery
Shares Cancer Models (PDCM Finder) & HCMI, Patient-derived xenografts, Patient-derived organoids.
- IdeaScore every preclinical model by how often it predicted the clinical result
Shares Cancer Models (PDCM Finder) & HCMI, Patient-derived xenografts, Patient-derived organoids.
- IdeaScore every model system on how well it predicted real trial results
Shares Patient-derived xenografts, Patient-derived organoids, Preclinical results do not reproduce.
- IdeaA funded organoid and PDX panel as the go/no-go gate before IND-enabling money
Shares Cancer Models (PDCM Finder) & HCMI, Patient-derived xenografts, Patient-derived organoids.
- IdeaProve your cell lines are what you say they are, or the paper is not published
Shares Cancer Models (PDCM Finder) & HCMI, Preclinical results do not reproduce.